Peregrine Capital Management LLC Has $5.67 Million Stake in Evolent Health, Inc. (NYSE:EVH)

Peregrine Capital Management LLC boosted its stake in Evolent Health, Inc. (NYSE:EVH) by 65.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 503,601 shares of the technology company’s stock after acquiring an additional 198,358 shares during the quarter. Peregrine Capital Management LLC’s holdings in Evolent Health were worth $5,666,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. R Squared Ltd bought a new position in shares of Evolent Health during the 4th quarter worth approximately $31,000. Covestor Ltd lifted its stake in Evolent Health by 138.1% in the third quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock valued at $40,000 after acquiring an additional 826 shares during the last quarter. AlphaCentric Advisors LLC acquired a new stake in Evolent Health in the fourth quarter valued at $61,000. KBC Group NV grew its position in shares of Evolent Health by 124.6% in the 4th quarter. KBC Group NV now owns 6,741 shares of the technology company’s stock valued at $76,000 after acquiring an additional 3,739 shares during the period. Finally, Dynamic Advisor Solutions LLC acquired a new position in shares of Evolent Health during the 4th quarter worth about $134,000.

Evolent Health Trading Up 0.7 %

Shares of Evolent Health stock opened at $10.09 on Wednesday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. The firm has a 50-day moving average of $10.82 and a 200-day moving average of $19.04. Evolent Health, Inc. has a 52-week low of $9.45 and a 52-week high of $35.00. The stock has a market cap of $1.18 billion, a PE ratio of -11.09 and a beta of 1.45.

Analyst Upgrades and Downgrades

EVH has been the subject of a number of research analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $15.00 price target on shares of Evolent Health in a report on Wednesday, February 12th. Royal Bank of Canada reduced their target price on Evolent Health from $20.00 to $17.00 and set an “outperform” rating for the company in a research note on Tuesday, January 14th. JPMorgan Chase & Co. dropped their price target on Evolent Health from $15.00 to $13.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 28th. Stephens reduced their price objective on shares of Evolent Health from $16.00 to $12.00 and set an “equal weight” rating for the company in a research report on Tuesday, January 21st. Finally, UBS Group decreased their price objective on shares of Evolent Health from $27.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, January 16th. One equities research analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $17.92.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.